Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 5/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156894 | 0.81 | TSHR (0.44) | NR3C2NOS2NUDT1MEN1KMT2A | |
| SCHEMBL12883355 | 0.81 | NOS2 (0.48) | NR3C2NOS3NOS1NOS2MEN1 | |
| SCHEMBL14156893 | 0.79 | NR3C2 (0.42) | NR3C2MEN1KMT2A | |
| SCHEMBL14156883 | 0.79 | POLB (0.43) | DYRK1AMEN1KMT2A | |
| SCHEMBL12895543 | 0.78 | DYRK1A (0.38) | TYK2DYRK1AMAOANR3C2CDK5 | |
| SCHEMBL2118437 | 0.75 | IGF1R (0.46) | TYK2DYRK1ANR3C2CDK5CDK5R1 | |
| SCHEMBL21017440 | 0.75 | RET (0.41) | MEN1KMT2A | |
| SCHEMBL13036454 | 0.74 | NR3C2 (0.49) | TYK2DYRK1ANR3C2CDK5CDK5R1 | |
| SCHEMBL17194956 | 0.74 | LOXL2 (0.41) | DYRK1AMAOASYKLOXLOXL2 | |
| SCHEMBL28056162 | 0.72 | MAOA (0.44) | DYRK1AMAOASYKLOXLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2021-08-19 | — | — | US | disclosed |
| US-11021462-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190152948-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-23 | — | — | US | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021462-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | TYK2 1/4885DYRK1A 58/4885MAOA 4470/4885 |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | TYK2 77/4885DYRK1A 487/4885MAOA 2173/4885 |
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | TYK2 1/4885DYRK1A 58/4885MAOA 4470/4885 |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | TYK2 1/4885DYRK1A 58/4885MAOA 4470/4885 |
| US-20190152948-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | TYK2 1/4885DYRK1A 58/4885MAOA 4470/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | TYK2 77/4885DYRK1A 487/4885MAOA 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.